Similarly, combining STING-based vaccines with anti-PD1 and agonist OX40 antibodies resulted in a better inhibition of tumor growth, as compared with the vaccine and anti-PD1 combination or control, by augmenting and prolonging the lifespan of the T cell response. Here, TNFRSF4 is linked to neoplasm.